IHE vs. IBB: Which iShares Healthcare ETF Is the Better Buy?

IHE vs IBB: iShares U.S. Pharmaceuticals ETF (IHE) charges a lower expense ratio (0.38% vs 0.44%), but has a much higher dividend yield (1.48% vs 0.22%, +1.26pp). Over 5 years it delivered higher total returns ($1,771 vs $1,226 growth of $1,000) with far lower max drawdown (16.02% vs 39.82%). The article frames the choice as defensive income/concentration (56 holdings; J&J 22.4%, Eli Lilly 22.3%) versus higher-growth biotech diversification (248 holdings; Vertex 8.1%, Amgen 7.8%, Gilead 6.8%) with more volatility.

Analysis

This is mostly a factor-rotation story, not a fundamental re-rating event. If allocators chase the combination of lower volatility and higher income, the marginal buyer is likely to favor mega-cap cash generators inside IHE, which means JNJ/LLY get the most mechanical support while the broader IBB basket sees less benefit because flows are diluted across far more names. The second-order implication is that biotech beta becomes more expensive to own unless there is a clear catalyst to justify the extra duration risk.

The key risk is that the comparison is backward-looking and anchored to a favorable five-year window for defensives. If rates ease or risk appetite broadens, IBB should outperform sharply because clinical-stage and platform biotech have more embedded operating leverage to lower discount rates, M&A, and financing access; that reversal would show up first in small/mid-cap biotech breadth, not in the biggest index names. Over 1-3 months, the market may treat this as a preference for yield and stability; over 6-18 months, the real driver is whether biotech capital markets reopen.

Contrarian view: IHE’s outperformance may already be crowded into the valuation of its top weights, so chasing it after a strong run risks paying up for quality. The more interesting alpha may be in selectively owning high-quality biotech within IBB, not the ETF itself, because the basket’s dispersion remains high and one positive FDA/clinical cycle can change index leadership quickly. Absent a macro catalyst, this is a relative-value trade, not a high-conviction directional healthcare call.

Key Decisions for Investors

• Put on a modest long IHE / short IBB pair for 1-3 months if healthcare flows stay defensive; target 3-5% relative outperformance, with a stop if IBB outperforms IHE by ~3% on improving biotech breadth.
• Favor JNJ and LLY as the primary beneficiaries of any IHE inflow wave; use pullbacks to add only if relative strength persists, because the incremental flow support is mechanical rather than fundamental.
• Avoid initiating fresh broad IBB exposure unless the sector gets a clear catalyst from lower rates, stronger FDA sentiment, or a pickup in biotech financing; otherwise the carry and volatility trade-off is poor.
• Set an alert on the IBB/IHE ratio reclaiming its 20- to 50-day trend: that would signal a regime shift back toward risk-on biotech and should trigger de-risking of the pair trade.